Highlight of 2023: CAR T cells driving precision therapy for autoimmune disease.

CAR T cell therapy has shown promising results in the treatment of autoimmune diseases. In 2023, five key studies were highlighted that are driving the development of CAR T cells to improve precision, safety, efficacy, and accessibility for the treatment of autoantibody-associated autoimmune diseases. CAR T cells targeting CD19 have been successful in achieving drug-free remission in patients with systemic lupus erythematosus. Other studies have explored the use of CAR T cells targeting B cell maturation antigen (BCMA) and chimeric autoantibody receptor (CAAR) T cells targeting specific autoantibodies in diseases such as neuromyelitis optica spectrum disorder and myasthenia gravis. Additionally, advancements have been made in the use of RNA-based CAR T cells, which offer potential advantages over DNA-based CAR T cells. These developments in precision cellular therapy hold promise for improving outcomes in autoimmune disease treatment. [Extracted from the article]

Copyright of Immunology & Cell Biology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)